Rsv Illness

NEW YORK — The CDC this week announced the release of more than 77,000 additional doses of nirsevimab to address an ongoing shortage of the monoclonal antibody in the United States.

For the first time, many Americans will enter the fall with multiple options to protect themselves against respiratory syncytial virus, even young children.

NEW YORK — In this video filmed at the Infectious Diseases in Children Symposium, John V. Williams, MD, describes multiple interventions in development against respiratory syncytial virus, which is currently surging in the United States.

Pfizer reported Thursday that its vaccine candidate for respiratory syncytial virus was nearly 86% effective in preventing severe illness in a phase 3 clinical trial of older adults.